The paucity of effective antifungals against Aspergillus and increasing resistance, the recognition of the importance of Aspergillus biofilm in several clinical settings, and reports of verapamil-a calcium channel blocker-efficacy against Candida biofilm and hyphal growth, and synergy with an azole antifungal in vitro, led to a study of verapamil ± voriconazole against Aspergillus. Broth macrod...

We describe a case of cerebral aspergillosis which was successfully treated with a combination of caspofungin and voriconazole. The patient remains in remission 18 months after stopping antifungal treatment. We discuss primary and salvage therapy of invasive aspergillosis with focus on cerebral involvement. Since historical data showed a fatal outcome in most cases, amphotericin B does not cros...

We report the occurrence of skin toxicities in pediatric oncology patients on concomitant treatment with voriconazole and methotrexate (MTX). Of 23 patients who received this combination, 11 patients suffered from cheilitis and/or photosensitivity. In contrast, only in 1 of 9 patients who received voriconazole without MTX was photosensitivity observed. A mechanism of action was not able to be i...

Voriconazole is active against Aspergillus and other filamentous fungi, but it has no activity against Zygomycetes. Iowa and Boston groups reported an increase in the incidence of zygomycosis in patients given prophylactic voriconazole. Long-term use of voriconazole might exert selective pressure for growth of resistant organisms however, reviews of data from several transplantation centers sho...

Voriconazole, a broad-spectrum triazole antifungal agent, is well absorbed, with a high oral bioavailability of 96% (6). Maximal plasma concentrations are observed 1 to 2 h after drug administration. The volume of distribution is estimated to be 4.6 liters/kg, and the plasma protein binding is 58%. A terminal elimination half-life (t1/2) of 8 h in CYP2C19 extensive metabolizers (EMs) and a t1/2...

OBJECTIVE To asses the cost-effectiveness of voriconazole in comparison to conventional amphotericin B and itraconazole for the treatment of invasive aspergillosis in the Netherlands. METHODS The cost-effectiveness of voriconazole in comparison to conventional amphotericin B or itraconazole was evaluated with a decision tree model followed by a life-time Markov model, focusing on long-term su...

This study aimed to explore any mutation in the CYP51 gene conferring azole resistance in Aspergillus flavus. Two voriconazole-resistant and 45 voriconazole-susceptible isolates were included in the study. Sequence analysis demonstrated a T1025C nucleotide change in CYP51C, resulting in the Y319H amino acid substitution in one resistant isolate. However, the earlier described T788G mutation in ...

Health technology The study compared the use of voriconazole and conventional amphotericin B deoxycholate (CAB). Voriconazole was administered at a dose of 6 mg/kg intravenously (IV) twice a day on day 1, followed by 4 mg/kg IV twice a day for at least 7 days, at which time patients could switch to oral voriconazole 200 mg twice daily. CAB was administered at a dose of 1.0 to 1.5 mg/kg IV once ...

22 23 24 Combined systemic and topical administration of voriconazole have been successfully used to 25 treat keratomycosis infection. No voriconazole eye drop product being commercially 26 available, we prepared a sterile eye drop solution (10 mg/ml). Voriconazole remains stable 27 over 30 days providing an eye drop solution suitable for topical treatment of fungal keratitis. 28 29 30 31 32 33...

background and purpose: candida species are the most opportunistic fungi affecting the nails and resulting in onychomycosis. in this study, we identified and evaluated in-vitro susceptibility of the recovered isolates against fluconazole (flc), voriconazole (vrc), and clotrimazole (clt) using the clinical and laboratory standards institute (clsi) m27-a3 document. materials and methods: from pat...